Lyell Immunopharma Stock Analysis
| LYEL Stock | USD 0.95 0.03 3.26% |
Lyell Immunopharma is undervalued with Real Value of 2.45 and Target Price of 7.0. The main objective of Lyell Immunopharma stock analysis is to determine its intrinsic value, which is an estimate of what Lyell Immunopharma is worth, separate from its market price. There are two main types of Lyell Immunopharma's stock analysis: fundamental analysis and technical analysis.
The Lyell Immunopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Lyell |
Lyell Stock Analysis Notes
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.5. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lyell Immunopharma has Price/Earnings To Growth (PEG) ratio of 0.68. The entity recorded a loss per share of 0.79. The firm had not issued any dividends in recent years. Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Lyell Immunopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. To find out more about Lyell Immunopharma contact Elizabeth Homans at 650 695 0677 or learn more at https://lyell.com.Lyell Immunopharma Quarterly Total Revenue |
|
Lyell Immunopharma Investment Alerts
| Lyell Immunopharma generated a negative expected return over the last 90 days | |
| Lyell Immunopharma has high historical volatility and very poor performance | |
| Lyell Immunopharma has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 130 K. Net Loss for the year was (234.63 M) with profit before overhead, payroll, taxes, and interest of 84.68 M. | |
| Lyell Immunopharma currently holds about 655.56 M in cash with (163.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lyell Immunopharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 62.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Lyell Immunopharma Director Hans bishop resigns |
Lyell Immunopharma Upcoming and Recent Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Lyell Largest EPS Surprises
Earnings surprises can significantly impact Lyell Immunopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.205 | -0.18 | 0.025 | 12 | ||
2024-11-08 | 2024-09-30 | -0.2 | -0.17 | 0.03 | 15 | ||
2024-02-28 | 2023-12-31 | -0.23 | -0.2 | 0.03 | 13 |
Lyell Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sc China Holding Ltd | 2024-09-30 | 3 M | Mic Capital Management Uk Llp | 2024-09-30 | 1.7 M | Opaleye Management Inc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Balyasny Asset Management Llc | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 1 M | Td Asset Management Inc | 2024-09-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 901.5 K | Mwg Management Ltd. | 2024-06-30 | 20.2 M | Orland Properties Ltd | 2024-06-30 | 15.1 M |
Lyell Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 263.89 M.Lyell Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.35) | (0.36) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.36) | (0.38) |
Management Efficiency
Lyell Immunopharma has return on total asset (ROA) of (0.1912) % which means that it has lost $0.1912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3322) %, meaning that it created substantial loss on money invested by shareholders. Lyell Immunopharma's management efficiency ratios could be used to measure how well Lyell Immunopharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.33. The value of Return On Capital Employed is expected to slide to -0.36. At this time, Lyell Immunopharma's Total Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 1 B this year, although the value of Other Assets will most likely fall to about 4.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.61 | 2.30 | |
| Tangible Book Value Per Share | 2.61 | 2.30 | |
| Enterprise Value Over EBITDA | (1.78) | (1.87) | |
| Price Book Value Ratio | 0.74 | 0.71 | |
| Enterprise Value Multiple | (1.78) | (1.87) | |
| Price Fair Value | 0.74 | 0.71 | |
| Enterprise Value | 4.7 B | 4.5 B |
Lyell Immunopharma benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Operating Margin -1.5 K | Beta (0.48) | Return On Assets (0.19) | Return On Equity (0.33) |
Technical Drivers
As of the 1st of December, Lyell Immunopharma secures the Mean Deviation of 4.85, standard deviation of 6.94, and Risk Adjusted Performance of (0.04). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lyell Immunopharma, as well as the relationship between them. Please verify Lyell Immunopharma mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Lyell Immunopharma is priced some-what accurately, providing market reflects its recent price of 0.95 per share. Given that Lyell Immunopharma is a hitting penny stock territory we strongly suggest to closely look at its jensen alpha.Lyell Immunopharma Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Lyell Immunopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Lyell Immunopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Lyell Immunopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lyell Immunopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lyell Immunopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lyell Immunopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lyell Immunopharma Outstanding Bonds
Lyell Immunopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lyell Immunopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lyell bonds can be classified according to their maturity, which is the date when Lyell Immunopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| US55087PAB04 Corp BondUS55087PAB04 | View |
Lyell Immunopharma Predictive Daily Indicators
Lyell Immunopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lyell Immunopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lyell Immunopharma Forecast Models
Lyell Immunopharma's time-series forecasting models are one of many Lyell Immunopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lyell Immunopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Lyell Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Lyell Immunopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lyell shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lyell Immunopharma. By using and applying Lyell Stock analysis, traders can create a robust methodology for identifying Lyell entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | -1.8 K | -1.7 K | |
| Operating Profit Margin | -1.9 K | -1.8 K | |
| Net Loss | -1.8 K | -1.7 K | |
| Gross Profit Margin | 0.72 | 0.76 |
Current Lyell Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lyell analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lyell analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 7.0 | Hold | 4 | Odds |
Most Lyell analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Lyell stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Lyell Immunopharma, talking to its executives and customers, or listening to Lyell conference calls.
Lyell Stock Analysis Indicators
Lyell Immunopharma stock analysis indicators help investors evaluate how Lyell Immunopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lyell Immunopharma shares will generate the highest return on investment. By understating and applying Lyell Immunopharma stock analysis, traders can identify Lyell Immunopharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 123.8 M | |
| Common Stock Shares Outstanding | 251 M | |
| Total Stockholder Equity | 655 M | |
| Property Plant And Equipment Net | 142.3 M | |
| Cash And Short Term Investments | 546.2 M | |
| Cash | 145.6 M | |
| Accounts Payable | 4.8 M | |
| Net Debt | -82.5 M | |
| 50 Day M A | 1.169 | |
| Total Current Liabilities | 34.5 M | |
| Other Operating Expenses | 247.1 M | |
| Non Current Assets Total | 195.3 M | |
| Non Currrent Assets Other | 4.5 M | |
| Stock Based Compensation | 47.1 M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.